Primary data · sourced from public filings·700+ listed companies · India-first·
Open screener
ἀλήθεια · aletheiaAncient Greek for truth — literally “un-forgetting”: the act of revealing reality, not merely stating it
← All posts
Sector Thesis·3 min read·Week 24

Synthetic Biology in India: Direct Products Lose to Embedded Plays

Direct synthetic biology products in India face a distribution graveyard. Embedded plays—biotech APIs for pharma, agri-biotech for seed companies—capture margins faster. The India Stack timeline favors embedded over brand.

ByAmit Tyagi·Fitoor Capital
Aletheia Insights · Weekly

Get 1 unfair insight every week from India's startup ecosystem.

Read by serious founders and investors. No fluff.

Blog Pass

Continue reading with Blog Pass

This piece is part of the Aletheia archive. This week’s drops are free — unlock every sector thesis, deal-flow breakdown and disclosure note with a Blog Pass.

₹999/mo·₹5,000/yrSave 58%
Get Blog Pass →

Amit Tyagi

Founder, AletheiaAI & GP, Fitoor Capital

Veteran of India's startup ecosystem. Writing about fundraising, investor psychology, and what it takes to build fundable startups in India.

Run a fundability check

India's only MRE-backed platform for founders and investors. Analyse your deck, find investors, and validate your raise strategy.

#synthetic-biology#india-biotech#embedded-vs-direct#distribution-strategy

Don’t miss the next one

One insight every week. No fluff.

Aletheia Insights · Weekly

One contrarian insight. Every week. No generic startup advice.

Join founders and investors building with better information.

Synthetic Biology in India: Direct Products Lose to Embedded Plays · Aletheia Insights